Novo Nordisk announced that the Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for expanded use of Tresiba®(insulin degludec) in children and adolescents aged 1-17 years with diabetes. Once the European Commission approves the label expansion, physicians in the European Union will be able to prescribe Tresiba® to children with type 1 and type 2 diabetes.
“When treating children and adolescents with diabetes, getting patients to target while minimizing side effects is always a priority,” said Dr Nandu Thalange, pediatric endocrinologist at Norfolk and Norwich University Hospital, Norwich, United Kingdom and the lead study investigator of the BEGIN® YOUNG 1 trial. “This latest CHMP recommendation for Tresiba® offers patients between the ages of 1 and 17 a new, once-daily basal insulin which allows patients to get to target with a reduced risk of hyperglycemia with ketosis versus insulin detemir.”
